Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned

Compass Therapeutics, Inc.

Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.
Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.
CTX-8371 cohort expansions in TNBC, NSCLC, HL initiated; dose-escalation data at ASCO 2026 poster.
CTX-10726 Phase 1 study initiated; initial clinical data expected in Q4 2026.
Cash and marketable securities $195M at Q1 2026; net loss $18.3M ($0.10/share); cash runway into 2028.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Compass Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $195 million in cash and marketable securities.

Period: the quarter ended March 31, 2026
Revenue: $195 million in cash and marketable securities
Result: reported results

Exact text from the filing

The Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) has also been initiated in the post-checkpoint inhibitor setting, with initial data expected [Q4 2026]. $195 million in cash and marketable securities at Q1 2026, which is expected to fund operations into 2028. BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX),

View on SEC.gov

Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.